Patent Description:
SAA is a precursor protein of amyloid A protein that is deposited in tissue upon amyloidosis, which is a serum protein with a molecular weight of approximately <NUM>,<NUM> (Non-Patent Document <NUM>). The serum concentration of SAA is known to increase in inflammatory diseases other than amyloidosis, and SAA is thus recognized as a sensitive inflammation marker (Non-Patent Document <NUM>).

Also, SAA is known to serve as an important inflammation marker in animal species other than humans (Non-Patent Documents <NUM> to <NUM>).

For example, Patent Document <NUM> discloses an apparent correlation between the SAA protein level in a milk sample obtained from the breast of a lactating mammal (e.g., bovine) and the inflammatory response level of the breast tissue (i.e., mastitis). Patent Document <NUM> discloses that infectious diseases can be distinguished from noninfectious causes of diseases based on the SAA concentration in a blood sample obtained from a mammal (e.g., horse) showing abnormal symptoms or actions.

For example, Patent Document <NUM> discloses a monoclonal antibody that specifically binds to human SAA, and Patent Document <NUM> discloses a monoclonal antibody that specifically binds to equine SAA. In the past, however, no reagents capable of measuring SAA derived from various animal species including humans involving the use of monoclonal antibodies were known.

Under the above circumstances, it is an object of the present invention to provide a reagent that can measure SAA derived from various animal species.

The present inventors have conducted concentrated studies in order to attain the above object. As a result, they found an animal species cross-reactive monoclonal antibody that recognizes SAA derived from various animal species from among anti-human SAA monoclonal antibodies. This has led to the completion of the present invention.

Specifically, the present invention includes the following.

<CIT> is the priority document of the present application.

With the method for immunologically measuring SAA according to the present invention, SAA, which is an inflammation marker for various animal species, can be easily detected or measured.

Hereafter, the present invention is described in detail.

The reagent for measuring SAA obtained from a plurality of (i.e., <NUM> or more) animal species used in the method according to the present invention (hereafter, referred to as "the reagent for measuring SAA according to the present disclosure") comprises an animal species cross-reactive anti-SAA monoclonal antibody or a fragment thereof. The animal species cross-reactive anti-SAA monoclonal antibody or a fragment thereof used in the method of the present invention (hereafter, referred to as "the monoclonal antibody or a fragment thereof according to the present disclosure") is a monoclonal antibody capable of recognizing SAA derived from various animal species and binding to such protein or a fragment thereof. With the use of the method for measuring SAA according to the present invention, SAA as an inflammation marker in various animal species can be immunologically measured.

Examples of SAA that the monoclonal antibody or a fragment thereof used in the method according to the present invention can recognize include SAA derived from animal species, such as a human, a bovine, a dog, a cat, a rabbit, a horse, a monkey, a pig, a sheep, a donkey, and a mouse.

The monoclonal antibody or a fragment thereof used in the method according to the present invention preferably binds to SAA by recognizing, as an epitope, the amino acid residues in the 80th to the 90th positions from the N terminus of the mature human serum amyloid A1 protein consisting of the amino acid sequence as shown in SEQ ID NO: <NUM>. The monoclonal antibody or a fragment thereof used in the method according to the present invention that binds to such epitope exhibits high binding property to SAA obtained from a plurality of animal species. A region of amino acid residues in other mature SAA protein (e.g., a mature SAA protein derived from an animal species other than a human) corresponding to a region in the vicinity of an amino acid residue in the 90th position from the N terminus of the mature human SAA1 protein consisting of the amino acid sequence as shown in SEQ ID NO: <NUM> to which the monoclonal antibody or a fragment thereof used in the method according to the present invention binds as an epitope, can be determined via, for example, alignment comparison between the amino acid sequence of the mature human SAA1 protein and the amino acid sequence of other mature SAA protein in accordance with a conventionally known method.

The monoclonal antibody used in the method according to the present invention may be of any immunoglobulin (Ig) class (e.g., IgA, IgG, IgE, IgD, IgM, or IgY) and any subclass (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, or IgA2). The immunoglobulin light chain may be a κ chain or λ chain.

Examples of the monoclonal antibody fragment used in the method according to the present invention include Fab, Fab', F(ab')<NUM>, Fv, Fd, and Fabc. Methods for preparing such fragments are known in the art. For example, such fragments can be obtained by digestion of antibody molecules with a protease such as papain or pepsin or via a known genetic engineering technique.

The monoclonal antibody used in the method according to the present invention can be obtained by preparing hybridomas from antibody-producing cells obtained from nonhuman mammals immunized with antigens (human SAA) (e.g., spleen cells or lymphatic cells) and myeloma cells via fusion, proliferating the obtained hybridomas in a selection medium containing hypoxanthine, aminopterin, and thymidine ("HAT medium"), cloning cells producing monoclonal antibodies exhibiting specific affinity to the antigens used for immunization (human SAA) or fragment peptide antigens thereof (e.g., a peptide antigen comprising a region in the vicinity of an amino acid residue in the 90th position from the N terminus of the mature human SAA1 protein consisting of the amino acid sequence as shown in SEQ ID NO: <NUM>), obtaining anti-human SAA monoclonal antibody-producing cell lines, proliferating the anti-human monoclonal antibody-producing cells in the mouse abdominal cavity, and purifying the antibody from the resulting ascites fluid. Examples of nonhuman mammals include rodents such as mice and rats. Myeloma cells derived from the same animal as the immunized animals are preferably used, and examples thereof include mouse myeloma cells and rat myeloma cells. Antibody-producing cells can be fused to myeloma cells with the use of polyethylene glycol (PEG) or via electrical fusion.

The prepared monoclonal antibody can be purified by a method known in the art, such as chromatography using a protein A or a protein G column, ion exchange chromatography, hydrophobic chromatography, salting out with ammonium sulfate, gel filtration, or affinity chromatography, in adequate combination.

The present invention relates to a method for immunologically measuring SAA comprising a step of measuring SAA using the reagent for measuring SAA as disclosed herein. Specifically, SAA in a biological sample derived from various animal species is brought into contact with the monoclonal antibody or a fragment thereof as disclosed herein in the reagent for measuring SAA as disclosed herein to cause an antigen-antibody reaction, and SAA in the sample is detected or measured based on the formed immune complex.

A biological sample that comprises or may comprise SAA is sufficient, and examples thereof include whole blood, serum, plasma, urine, puncture fluid, sweat, saliva, lymph, and spinal fluid samples.

Examples of methods for immunological measurement include: single radial immunodiffusion (not part of the invention) comprising observing the expression of a precipitate line formed by an immune complex resulting from binding of the monoclonal antibody or a fragment thereof as disclosed herein to SAA in the biological sample on an agar plate; enzyme immunoassay (EIA) (not part of the invention) or radioimmunoassay (not part of the invention) involving the use of the monoclonal antibody or a fragment thereof as disclosed herein labeled with an enzyme or radioactive isotope; and use of an insoluble carrier comprising the monoclonal antibody or a fragment thereof as disclosed herein immobilized thereon. Examples of insoluble carriers include particles such as latex particles (such as polyethylene or polystyrene particles), alumina particles (not encompassed by the invention), silica particles (not encompassed by the invention), gold colloid particles (not encompassed by the invention), and magnetic particles (not encompassed by the invention). Among such insoluble carriers, latex particles are preferable, and polystyrene latex particles are particularly preferable.

Insoluble carrier particles are preferably of <NUM> to <NUM> in diameter, and more preferably of <NUM> to <NUM> in diameter.

An antibody or a fragment thereof can be immobilized on an insoluble carrier in accordance with a conventional technique. Specifically, an antibody or a fragment thereof is mixed with an insoluble carrier, and an antibody or a fragment thereof is allowed to physically adsorb to the insoluble carrier surface. Thus, an antibody or a fragment thereof can be immobilized on the insoluble carrier.

When an insoluble carrier comprising an amino or carboxyl group introduced on its surface is used, an antibody or a fragment thereof can be immobilized on the insoluble carrier surface via a chemical bond involving the use of a glutaraldehyde or carbodiimide reagent.

Examples of methods involving the use of insoluble carriers include: a latex turbidimetric immunoassay involving the use of latex particles comprising the monoclonal antibody or a fragment thereof used in the method according to the present invention immobilized thereon; gold colloid-based agglutination colorimetry (not part of the invention) involving the use of gold colloid particles comprising the monoclonal antibody or a fragment thereof as disclosed herein immobilized on gold colloids; and immunochromatographic assays (not part of the invention) involving the use of the monoclonal antibody or a fragment thereof as disclosed herein labeled with metal colloids and a capture antibody that captures an immune complex of the monoclonal antibody or a fragment thereof as disclosed herein and SAA on a membrane such as nitrocellulose membrane. According to the latex turbidimetric immunoassay, specifically, latex particles comprising the monoclonal antibody or a fragment thereof used in the method according to the present invention immobilized on the latex are allowed to react with SAA in a biological sample, and SAA is measured based on agglutination of latex particles as a result of formation of the immune complex and changes in turbidity caused by latex agglutination. According to immunochromatographic assays (not part of the invention), a biological sample is supplied onto a membrane such as nitrocellulose membrane, SAA in the biological sample reacts with the monoclonal antibody or a fragment thereof as disclosed herein in a label-reagent-retaining region that retains the monoclonal antibody or a fragment thereof as disclosed herein labeled with metal colloids or the like to form an immune complex, the immune complex migrates on the membrane by the capillary action, the immune complex is captured by a capture antibody immobilized in a given position on the membrane, and SAA is detected based on the color developed as a result of the capturing.

As described above, the reagent for measuring SAA as disclosed herein can be used for a method for immunologically measuring SAA. When the method for immunological measurement involves the use of an insoluble carrier, for example, the reagent for measuring SAA as disclosed herein can contain an insoluble carrier comprising the monoclonal antibody or a fragment thereof as disclosed herein immobilized thereon, such as a latex solution containing latex particles. When immunochromatographic assays (not part of the invention) are performed, the reagent for measuring SAA as disclosed herein can be used for an immunochromatographic device composed of an insoluble carrier comprising the monoclonal antibody or a fragment thereof as disclosed herein immobilized thereon, such as gold colloids, and a membrane such as nitrocellulose membrane comprising the monoclonal antibody or a fragment thereof as disclosed herein immobilized thereon (e.g., a membrane such as nitrocellulose membrane supported on a carrier comprising a sample supply region, a label-reagent-retaining region that retains the monoclonal antibody or a fragment thereof as disclosed herein labeled with metal colloids or the like, and a detection region comprising a capture antibody immobilized on a given position).

In addition to the monoclonal antibody or a fragment thereof used in the method according to the present invention, the reagent for measuring SAA used in the method according to the present invention can comprise a buffer that imparts a pH level necessary for immunological reaction, a reaction enhancer that accelerates immunological reaction, a reaction stabilizer or blocker that suppresses non-specific reaction, a preservative that improves storage stability of a reagent, such as sodium azide, and the like.

Examples of buffers include the following.

Among such buffers, Good's buffers, such as HEPES and PIPES, adjust a pH level to an advantageous level for the immunological reaction. In addition, the influence thereof imposed on proteins is small. Thus, such buffers are particularly preferable. A pH level necessary for the immunological reaction is <NUM> to <NUM>, and it is preferably <NUM> to <NUM>.

As a reaction enhancer, for example, polyethylene glycol and dextran sulfate are known. In addition, BSA (bovine serum albumin), animal serum, IgG, IgG fragments (Fab and Fc), albumin, milk protein, amino acid, polyamino acid, choline, a polysaccharide such as sucrose, gelatin, degraded gelatin, casein, a polyhydric alcohol such as glycerin, and the like are known to effectively stabilize the reaction or inhibit the non-specific reaction in the immunological reaction in the form of reaction stabilizers or blockers.

The reagent for measuring SAA used in the method according to the present invention comprising various components described above can be supplied in a liquid or dry state. In order to realize distribution of the reagent in a liquid state, the reagent may further be supplemented with, for example, various surfactants, saccharides, or inactive proteins, so as to improve protein stability. Such stabilizers are also effective as stabilizers or excipients when drying the reagent.

Hereafter, the present invention is described in greater detail with reference to the Examples.

In the Comparative Examples and the Examples below, epitopes of the mature human SAA1 protein (the amino acid sequence as shown in SEQ ID NO: <NUM>) to which monoclonal antibodies bind are as described below:.

Whether or not bovine SAA could be measured using a latex reagent comprising the anti-human SAA polyclonal antibody immobilized on polystyrene latex particles was examined.

The anti-human SAA polyclonal antibody was immobilized on polystyrene latex particles of <NUM> in diameter.

The anti-human SAA polyclonal antibody was immobilized on the polystyrene latex particles in accordance with a conventional technique. Specifically, the anti-human SAA polyclonal antibody was mixed with polystyrene latex, so as to allow the anti-human SAA polyclonal antibody to physically adsorb on the polystyrene latex surface. Thus, the anti-human SAA polyclonal antibody was immobilized on the polystyrene latex particles.

Bovine plasma specimens sampled with time before and after surgery were measured by using the above latex reagent with the Hitachi <NUM> automatic analyzer (Hitachi High-Technologies). Specifically, <NUM>µl of the plasma specimen was mixed with <NUM>µl of the first reagent (<NUM> HEPES buffer, pH <NUM>), the mixture was incubated at <NUM> for <NUM> minutes, <NUM>µl of the second reagent (a polyclonal antibody-immobilized latex solution containing <NUM> HEPES buffer, pH <NUM>) was added thereto, the reaction was allowed to proceed at <NUM>, and changes in the absorbance were measured at the dual wavelength of <NUM>/<NUM> (sub wavelength/main wavelength) for approximately <NUM> minutes after the second reagent was added.

The SAA concentration in the plasma specimens was calculated from the calibration curve obtained by measuring the sample with known SAA concentration.

The SAA concentration in the bovine plasma specimens sampled with time before and after surgery was <NUM> to <NUM>/l, which was below the measurement range of the SAA reagent prepared with the polyclonal antibody (<NUM> to <NUM>/l) (<FIG>).

The SAA reagent prepared with the use of the anti-human SAA polyclonal antibody exhibited low reactivity with bovine SAA, and, accordingly, bovine SAA could not be measured. While bovine SAA could be measured via EIA involving the use of the polyclonal antibody as described in Example <NUM>, it could not be measured via the latex turbidimetric immunoassay.

The monoclonal antibody reacting with bovine SAA was screened.

The bovine plasma specimens sampled before and after surgery were immobilized on a microplate (antigen immobilization), the anti-human SAA polyclonal antibodies and the anti-human SAA monoclonal antibodies (Clones <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, and <NUM> shown in Table <NUM> of Patent Document <NUM>) were allowed to react therewith, and reactivity was then examined via EIA in which the POD-labeled anti-rabbit IgG antibody or the POD-labeled anti-rat IgG antibody was allowed to react.

Concerning reactivity with the bovine plasma specimens at <NUM> days after surgery, the reactivity of Clone <NUM> was the highest, followed by Clone <NUM>, Clone <NUM>, and the polyclonal antibody in descending order, and no difference was observed in reactivity of other clones before and after surgery (<FIG>).

It was confirmed that the anti-human SAA polyclonal antibody reacted with the bovine plasma while the reaction level was low and the monoclonal antibodies (Clone <NUM> and Clone <NUM>) did not react with the bovine plasma specimens at the acute stage. Among the monoclonal antibodies used for screening, <NUM> monoclonal antibody clones (Clone <NUM>, Clone <NUM>, and Clone <NUM>) that would react with the bovine plasma specimens at the acute stage were identified.

The latex reagents for measuring animal SAA were examined.

Latex reagents were prepared with the use of the anti-human SAA monoclonal antibody (Clone <NUM>) and polystyrene latex particles of <NUM> in diameter or of <NUM> and <NUM> in diameter, and the dilution series of serum specimens with known SAA concentration and bovine, dog, and cat serum specimens were measured. As a comparative example, the measurement with commercially available LZ test "Eiken" SAA (Eiken Chemical Corporation) was also carried out.

The anti-human SAA monoclonal antibody was immobilized on the polystyrene latex particles in accordance with a known method. Specifically, the anti-human SAA monoclonal antibody was mixed with polystyrene latex, so as to allow the anti-human SAA monoclonal antibody to physically adsorb on the polystyrene latex surface. Thus, the anti-human SAA monoclonal antibody was immobilized on the polystyrene latex particles.

The dilution series of serum specimens with known SAA concentration (human SAA) and bovine, dog, and cat serum specimens were measured with the use of the Hitachi <NUM> automatic analyzer (Hitachi High-Technologies). Specifically, <NUM>µl of the serum specimen was mixed with <NUM>µl of the first reagent (<NUM> HEPES buffer, pH <NUM>), the mixture was incubated at <NUM> for <NUM> minutes, <NUM>µl of the second reagent (a monoclonal antibody-immobilized latex solution containing <NUM> HEPES buffer, pH <NUM>) was added thereto, the reaction was allowed to proceed at <NUM>, and changes in the absorbance were measured at the dual wavelength of <NUM>/<NUM> (sub wavelength/main wavelength) for approximately <NUM> minutes after the second reagent was added.

The SAA concentration in the bovine, dog, and cat serum specimens were calculated from the calibration curve obtained by measuring the sample with known SAA concentration.

<FIG> shows the results of measurement of the dilution series of serum specimens with known SAA concentration (human SAA) with the use of the SAA reagent comprising polystyrene latex particles of <NUM> in diameter and the monoclonal antibody (Clone <NUM>) immobilized thereon. With the use of the SAA reagent comprising Clone <NUM> immobilized thereon, a fluctuation was observed in changes in the absorbance (ΔAbs) in the dilution series, and the calibration curve was thus obtained.

The monoclonal antibody (Clone <NUM>) was immobilized on two types of latex particles (i.e., particles of <NUM> in diameter and particles of <NUM> in diameter), and a latex reagent (SAA-M) comprising these two <NUM> types of latex particles at <NUM>:<NUM> was prepared. <FIG> shows the results of measurement of the dilution series of serum specimens with known SAA concentration (calibration curve).

<FIG> shows the results of measurement of the bovine, dog, and cat serum specimens. SAA in the bovine, dog, and cat specimens could be measured with the use of the latex reagent (SAA-M) prepared by immobilizing the monoclonal antibody (Clone <NUM>) on two types of latex particles (i.e., particles of <NUM> in diameter and particles of <NUM> in diameter). With the use of the LZ test "Eiken" SAA (LZ-SAA), in contrast, the SAA level of the bovine and dog serum specimens was below the measurement range of the LZ test "Eiken" SAA; that is, the SAA level in the bovine and dog specimens could not be measured with the use of the LZ test "Eiken" SAA. In the case of the dog specimen, a larger fluctuation was observed compared with the level measured with the use of a commercially available reagent for measuring canine CRP, and a larger fluctuation was observed in the cat specimen compared with the results attained with the use of the LZ test "Eiken" SAA.

With the use of the monoclonal antibody (Clone <NUM>) binding to SAA by recognizing, as an epitope, a region in the vicinity of an amino acid residue in the 90th position from the N terminus of the mature human SAA1 protein consisting of the amino acid sequence as shown in SEQ ID NO: <NUM>, SAA latex reagents reacting with SAA obtained from a bovine, a dog, and a cat can be prepared.

Whether or not SAA of various animal species could be measured with the use of the monoclonal antibody (Clone <NUM>) binding to SAA by recognizing, as an epitope, a region in the vicinity of an amino acid residue in the 90th position from the N terminus of the mature human SAA1 protein consisting of the amino acid sequence as shown in SEQ ID NO: <NUM> was examined.

SAA in various animal species was measured using the latex reagent immobilizing the monoclonal antibody (Clone <NUM>) (animal SAA reagent).

As a comparative example, measurement was carried out in the same manner with the use of the LZ test "Eiken" SAA (LZ-SAA) described in Example <NUM>. An animal species (rabbit) that would not react with the LZ test "Eiken" SAA (LZ-SAA) was subjected to measurement of CRP that would be elevated in case of inflammatory diseases as with SAA for reference.

The animal SAA reagent was prepared in the same manner as in Example <NUM> except for the use of polystyrene latex particles of <NUM> in diameter.

SAA in various animal specimens was measured with the use of the Hitachi <NUM> automatic analyzer (Hitachi High-Technologies). Specifically, <NUM>µl each of various specimens was mixed with <NUM>µl of the first reagent (<NUM> HEPES buffer, pH <NUM>), the mixture was incubated at <NUM> for <NUM> minutes, <NUM>µl of the second reagent (a monoclonal antibody-immobilized latex solution containing <NUM> HEPES buffer, pH <NUM>) was added thereto, the reaction was allowed to proceed at <NUM>, and changes in the absorbance were measured at wavelength of <NUM> for approximately <NUM> minutes after the second reagent was added.

The SAA concentration in various animal specimens was calculated from the calibration curve obtained by measuring the sample with known SAA concentration.

While SAA could not be measured in the comparative example (the LZ test "Eiken" SAA) (below the measurement sensitivity), SAA in specimens obtained from various animals (i.e., a bovine, a horse, a monkey, a donkey, a sheep, a pig, a mouse, and a rabbit) could be measured with the use of the animal SAA reagent (the monoclonal antibody (Clone <NUM>) binding to SAA by recognizing, as an epitope, a region in the vicinity of an amino acid residue in the 90th position from the N terminus of the mature human SAA1 protein consisting of the amino acid sequence as shown in SEQ ID NO: <NUM>; corresponding to "the reagent for measuring SAA according to the present disclosure").

With the use of the animal SAA reagent (the monoclonal antibody (Clone <NUM>)), SAA in various animal species can be measured.

The monoclonal antibodies obtained from Clone <NUM> and Clone <NUM> binding to SAA by recognizing, as an epitope, a region in the vicinity of an amino acid residue in the 90th position from the N terminus of the mature human SAA1 protein consisting of the amino acid sequence as shown in SEQ ID NO: <NUM> were examined as to whether or not SAA in various animal specimens could be measured as with the case of the monoclonal antibody of Clone <NUM>.

Various animal serum samples obtained from a human, a cat, a dog, a horse, a bovine, a monkey, a capybara, and a mouse were immobilized on a microplate (antigen immobilization), the anti-SAA monoclonal antibodies obtained from Clone <NUM>, Clone <NUM>, and Clone <NUM> were allowed to react therewith, and reactivity was then examined via EIA in which the POD-labeled anti-rat IgG antibody was allowed to react.

The results of measurement are shown in <FIG>. The symbols "∘" and "×" used in the table shown in <FIG> indicate the presence and the absence of the reaction (presence: ∘, absence: ×), respectively. Concerning the "Blank-corrected value" shown in the table in <FIG>, the reaction is determined to have occurred (+) when the blank-corrected value is <NUM> or higher by taking dispersion into consideration.

With the use of "the monoclonal antibody of Clone <NUM> that binds to SAA by recognizing, as an epitope, a region in the vicinity of an amino acid residue in the 90th position from the N terminus of the mature human SAA1 protein consisting of the amino acid sequence as shown in SEQ ID NO: <NUM> according to the present disclosure" and "the monoclonal antibody of Clone <NUM> that binds to SAA by recognizing, as an epitope, a region in the vicinity of an amino acid residue in the 90th position from the N terminus of the mature human SAA1 protein consisting of the amino acid sequence as shown in SEQ ID NO: <NUM> according to the present disclosure," SAA in various animal specimens could be measured as with the use of "the monoclonal antibody of Clone <NUM> that binds to SAA by recognizing, as an epitope, a region in the vicinity of an amino acid residue in the 90th position from the N terminus of the mature human SAA1 protein consisting of the amino acid sequence as shown in SEQ ID NO: <NUM> according to the present disclosure. " As shown in the chart shown in <FIG>, a correlational coefficient of Clone <NUM> to Clone <NUM> was <NUM>, and that of Clone <NUM> to Clone <NUM> was <NUM>.

It was suggested that the monoclonal antibody of Clone <NUM> and the monoclonal antibody of Clone <NUM> exhibit equivalent properties as the monoclonal antibody of Clone <NUM>.

The amino acid sequences of the mature human SAA1 protein consisting of the amino acid sequence as shown in SEQ ID NO: <NUM> to which the monoclonal antibodies obtained from Clone <NUM>, Clone <NUM>, and Clone <NUM> would bind as epitopes were examined.

As shown in Table <NUM> and <FIG>, peptides derived from the mature human SAA1 protein were immobilized on glass slides (antigen immobilization) to prepare arrays.

Subsequently, the anti-SAA monoclonal antibodies obtained from Clone <NUM>, Clone <NUM>, and Clone <NUM> were allowed to react with the peptides on the arrays, and the biotin-labeled goat anti-rat IgG antibody was then allowed to react therewith. Thereafter, fluorescence-labeled streptavidin was allowed to react with the arrays, and reactivity of anti-SAA monoclonal antibodies to the peptides was examined.

Positive controls shown in Table <NUM> and <FIG> are as shown below:.

The results are shown in <FIG> and <FIG>.

As shown in <FIG> and <FIG>, the anti-SAA monoclonal antibodies obtained from Clone <NUM>, Clone <NUM>, and Clone <NUM> were found to sufficiently bind to Peptides #<NUM> to #<NUM>.

Claim 1:
A method for immunologically measuring serum amyloid A comprising a step of measuring serum amyloid A using a reagent for measuring serum amyloid A from a plurality of animal species, said reagent comprising an animal species cross-reactive anti-serum amyloid A monoclonal antibody or a fragment thereof,
wherein said animal species cross-reactive anti-serum amyloid A monoclonal antibody or a fragment thereof specifically binds to, as the serum amyloid A protein epitope, the amino acid residues in the 80th to the 90th positions from the N terminus of the mature human serum amyloid A1 protein consisting of the amino acid sequence as shown in SEQ ID NO: <NUM>,
wherein said fragment of monoclonal antibody is selected from the group consisting of Fab, Fab', F(ab')<NUM>, Fv, Fd and Fabc,
wherein the plurality of animal species are a plurality of animal species selected from the group consisting of a human, a bovine, a dog, a cat, a rabbit, a horse, a monkey, a pig, a sheep, a donkey, and a mouse, and
wherein the method for immunological measurement is the latex turbidimetric immunoassay.